INSILICO (03696) Nominates Peripherally Restricted VAV1 Molecular Glue Degrader with Potential for Treating Multiple Autoimmune Diseases
Insilico Medicine (03696) announces that the Company has nominated ISM9546 as a preclinical candidate compound (PCC). It is an innovative, orally available, peripherally restricted VAV1 molecular glue degrader with potential for treating multiple autoimmune diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Enabled by Insilico Medicine's proprietary Pharma.AI solutions, ISM9546 is not only the Company's 35th PCC nominated since 2021, but also achieves a balance between efficacy and safety, demonstrating nanomolar-level activity in multiple cell assays and, through its peripherally restricted characteristics, potentially reducing risks associated with the central nervous system (CNS).
INSILICO (03696) announces that the company has nominated ISM9546 as a preclinical candidate compound (PCC). It is an innovative, orally administered, peripherally restricted VAV1 molecular glue degrader with potential for treating multiple autoimmune diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA), among others. Empowered by INSILICO's proprietary Pharma.AI solution, ISM9546 is not only the company's 35th PCC nominated since 2021, but also achieves a balance between efficacy and safety, demonstrating nanomolar-level activity in multiple cellular assays and, through its peripherally restricted characteristics, potentially reducing risks associated with the central nervous system (CNS).
Related Articles
Wall Street giants' earnings reports kick off tonight: With share prices mired in a technical correction, a 20% profit growth forecast fails to dispel threefold anxiety.
Soochow: Synergy Between Model Capabilities and Production Workflows Brings AI Film and Television Industrialization into a Validation Phase
GMTEight List of A-share restricted sales and lifting restrictions | October 13
Wall Street giants' earnings reports kick off tonight: With share prices mired in a technical correction, a 20% profit growth forecast fails to dispel threefold anxiety.
Soochow: Synergy Between Model Capabilities and Production Workflows Brings AI Film and Television Industrialization into a Validation Phase
GMTEight List of A-share restricted sales and lifting restrictions | October 13
